BDI reps are on-call for all your emergency and after-hours ordering. Call 1-800-948-9834
to place an order today.
BDI Pharma is a Verified-Accredited Wholesale Distributor one
of 34 active members of the HDMA, and a
member of HISCI. Always rest assured your product is being handled
with the utmost care and professionalism.
Healthcare doesn't stop with humans. See how our level of expertise has reached
the world of our special friends at www.4legPharma.com
Effective April 1, 2012 through June 30, 2012. Visit the Centers for Medicare
& Medicaid Services for more information.
|
|
IMOGAM® Rabies-HT
|
Manufacturer: Sanofi
-
Pasteur |
| Generic
Name: Rabies Immune
Globulin (Human) Intramuscular,
Heat Treated |
| |
Indications: Rabies
Immune Globulin (Human) Heat
Treated, Imogam Rabies HT, is
indicated for individuals
suspected of exposure to rabies,
particularly severe exposure,
with one exception: persons who
have been previously immunized
with Rabies Vaccine prepared
from human diploid cells (HDCV)
in a pre-exposure or
postexposure treatment series
should receive only vaccine.
Persons who have been previously
immunized with Rabies Vaccines
other than HDCV, RVA (Rabies
Vaccine Adsorbed), or PCEC
(Purified Chick Embryo Cell
Vaccine) vaccines should have
confirmed adequate rabies
antibody titers if they are to
receive only vaccine.
Imogam
Rabies HT should be injected
as promptly as possible after
exposure along with the first
dose of vaccine. If initiation
of treatment is delayed for any
reason, Imogam Rabies HT and
the first dose of vaccine should
still be given, regardless of
the interval between exposure
and treatment. Imogam Rabies
HT may be given up to eight days
after the first dose of vaccine
was given.
Rabies virus is usually
transmitted by the bite of a
rabid animal (dog, bat, etc.)
but can occasionally penetrate
abraded skin contaminated with
the saliva of infected animals.
Progress of the virus after
exposure is believed to follow a
neural pathway and the time
between exposure and clinical
rabies is a function of the
proximity of the bite (or
abrasion) to the central nervous
system and the dose of virus
injected. The incubation is
usually 2 to 6 weeks but can be
longer. After severe bites about
the face and neck and arms, it
may be as short as 10 days.
After initiation of the vaccine
series (human diploid cell
origin), it takes approximately
one week for development of
immunity to rabies; therefore,
the value of immediate passive
immunization with rabies
antibodies in the form of Rabies
Immune Globulin (Human) cannot
be overemphasized.
Recommendations for
passive and/or active
immunization after exposure to
an animal suspected of having
rabies have been outlined by the
WHO29 and by the United States
Public Health Service Advisory
Committee on Immunization
Practices (ACIP).
Each
exposure to possible rabies
infection must be individually
evaluated. Local or state public
health officials should be
consulted if questions arise
about the need for rabies
prophylaxis.
|
| |
|
Available Sizes |
Size |
NDC Numbers |
PI |
MSDS |
| Imogam |
2mL vial |
49281-0190-20 |
PI |
MSDS |
| Imogam |
10mL vial |
49281-0190-10 |
PI |
MSDS |
| |
| |
| Clinical Data:
For any questions or for further
information related to Imogam,
Rabies-HT,
clinical pharmacology, additional indications and
usages, contraindications,
warnings, precautions, adverse
reactions, dosage,
administration and / or storage
of this product, please
contact
BDI Pharma or
call
1-800-948-9834. |
| |
| |
| |
|